

CITATION REPORT

List of articles citing

Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selon

DOI: 10.1111/liv.13706

Liver International, 2018, 38, 1849-1859.

Source: <https://exaly.com/paper-pdf/69052811/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
70	Reply. <i>Hepatology</i> , 2018 , 68, 390	11.2	
69	Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD. <i>Diseases (Basel, Switzerland)</i> , 2018 , 6,	4.4	12
68	Future trends in the treatment of non-alcoholic steatohepatitis. <i>Pharmacological Research</i> , 2018 , 134, 289-298	10.2	40
67	The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study. <i>JHEP Reports</i> , 2019 , 1, 154-161	10.3	14
66	Obesity and Hepatocarcinogenesis. 2019 , 87-102		
65	Phase III drug pipelines in the treatment of non-alcoholic steatohepatitis. <i>Hepatology Research</i> , 2019 , 49, 1256-1262	5.1	36
64	PROs of Patient-reported Outcomes for Nonalcoholic Fatty Liver Disease and Effects on Treatment for Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1950-1953	6.9	1
63	Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2093-2100.e3	6.9	18
62	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2552-2560.e10	6.9	33
61	Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2085-2092.e1	6.9	41
60	Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment. <i>Gene Expression</i> , 2019 , 19, 175-185	3.4	9
59	A Comprehensive Review of Patient-reported Outcomes in Patients With Chronic Liver Diseases. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, 331-341	3	21
58	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019 , 69, 2672-2682	11.2	557
57	Non-alcoholic fatty liver disease - A global public health perspective. <i>Journal of Hepatology</i> , 2019 , 70, 531-544	13.4	685
56	Transforming growth factor (TGF) cross-talk with the unfolded protein response is critical for hepatic stellate cell activation. <i>Journal of Biological Chemistry</i> , 2019 , 294, 3137-3151	5.4	25
55	Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. <i>Cancer Letters</i> , 2019 , 440-441, 82-93	9.9	55
54	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. <i>Endocrine Reviews</i> , 2020 , 41,	27.2	56

53	Redundant role of ASK1-mediated p38MAPK activation in human platelet function. <i>Cellular Signalling</i> , 2020 , 68, 109528	4.9	5
52	Nonalcoholic Fatty Liver Disease. <i>Handbook of Experimental Pharmacology</i> , 2020 , 1	3.2	2
51	ASK1 inhibition: a therapeutic strategy with multi-system benefits. <i>Journal of Molecular Medicine</i> , 2020 , 98, 335-348	5.5	38
50	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020 , 158, 1611-1625.e12	13.3	234
49	Current and new pharmacotherapy options for non-alcoholic steatohepatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 953-967	4	17
48	Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 629-636	4	7
47	The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021 , 160, 1608-1619.e13	13.3	15
46	Integrating Patient-Reported Outcomes Within Routine Hepatology Care: A Prompt to Action. <i>Hepatology</i> , 2021 , 73, 1570-1580	11.2	3
45	Selonsertib, a potential drug for liver failure therapy by rescuing the mitochondrial dysfunction of macrophage via ASK1-JNK-DRP1 pathway. <i>Cell and Bioscience</i> , 2021 , 11, 9	9.8	3
44	Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. <i>Drugs</i> , 2021 , 81, 419-443	12.1	2
43	Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update. <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 329-338	3	7
42	Alcoholic and Non-Alcoholic Liver Diseases: Promising Molecular Drug Targets and their Clinical Development. <i>Current Drug Discovery Technologies</i> , 2021 , 18, 333-353	1.5	1
41	Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2021 , 5, 1201-1211	6	4
40	Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B. <i>JHEP Reports</i> , 2021 , 3, 100280	10.3	0
39	Current and Emerging Approaches for Hepatic Fibrosis Treatment. <i>Gastroenterology Research and Practice</i> , 2021 , 2021, 6612892	2	1
38	Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	8
37	Selonsertib Alleviates the Progression of Rat Osteoarthritis: An and Study. <i>Frontiers in Pharmacology</i> , 2021 , 12, 687033	5.6	1
36	c-Jun N-terminal kinase (JNK) signaling contributes to cystic burden in polycystic kidney disease.		0

35	Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. <i>JHEP Reports</i> , 2021 , 3, 100305	10.3	13
34	Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. <i>Journal of Clinical and Translational Hepatology</i> , 2021 , 9, 40-50	5.2	4
33	Population Management of Nonalcoholic Fatty Liver Disease. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2019 , 36, 72-82	0.7	2
32	A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates. <i>Scientific Reports</i> , 2021 , 11, 22765	4.9	3
31	New Therapeutic Targets for Hepatic Fibrosis in the Integrin Family, $\alpha 11$ and $\beta 11$, Induced Specifically on Activated Stellate Cells. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	0
30	Nonalcoholic fatty liver disease: lifestyle and quality of life. <i>Hormones</i> , 2021 , 21, 41	3.1	2
29	Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
28	c-JUN n-Terminal Kinase (JNK) Signaling in Autosomal Dominant Polycystic Kidney Disease.. <i>Journal of Cellular Signaling</i> , 2022 , 3, 62-78	1	
27	Probing the interaction of Selonsertib with human serum albumin: In silico and in vitro approaches.. <i>Current Topics in Medicinal Chemistry</i> , 2022 ,	3	1
26	The contribution of daytime sleepiness to impaired quality of life in NAFLD in an ethnically diverse population.. <i>Scientific Reports</i> , 2022 , 12, 5123	4.9	
25	Serum Amyloid A1 Exacerbates Hepatic Steatosis via TLR4 Mediated NF- κ B Signaling Pathway.. <i>Molecular Metabolism</i> , 2022 , 101462	8.8	2
24	c-Jun N-terminal kinase (JNK) signaling contributes to cystic burden in polycystic kidney disease.. <i>PLoS Genetics</i> , 2021 , 17, e1009711	6	0
23	Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis.. <i>Acta Pharmacologica Sinica</i> , 2021 ,	8	2
22	Strategies for Improving Photodynamic Therapy Through Pharmacological Modulation of the Immediate Early Stress Response.. <i>Methods in Molecular Biology</i> , 2022 , 2451, 405-480	1.4	1
21	Chronic liver disease questionnaire to manage patients with chronic liver diseases.. <i>Hepatology Research</i> , 2022 ,	5.1	
20	Advances in Immunosuppressive Agents Based on Signal Pathway. <i>Frontiers in Pharmacology</i> , 2022 , 13,	5.6	1
19	The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. <i>JHEP Reports</i> , 2022 , 100525	10.3	0
18	Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life.		0

- 17 Anti-neuroinflammatory effects and brain pharmacokinetic properties of selonsertib.
- 16 Association between hepatic steatosis and fibrosis indices and dietary habits, physical activity, and quality of life. **2022**,
- 15 Measuring, Analyzing, and Presenting Work Productivity Loss in Randomized Controlled Trials: A Scoping Review. **2022**,
- 14 Vitality, mental health and role-physical mediate the influence of coping on depressive symptoms and self-efficacy in patients with non-alcoholic fatty liver disease: A cross-sectional study. **2022**, 162, 111045 ○
- 13 An in vitro fibrotic liver lobule model through sequential cell-seeding of HSCs and HepG2 on 3D-printed poly(glycerol sebacate) acrylate scaffolds. ○
- 12 Geographical similarity and differences in the burden and genetic predisposition of NAFLD. 3
- 11 Tanshinone IIA Ameliorates Nonalcoholic Steatohepatitis in Mice by Modulating Neutrophil Extracellular Traps and Hepatocyte Apoptosis. **2022**, 2022, 1-13 ○
- 10 Thioredoxin-interacting protein deficiency protects against severe acute pancreatitis by suppressing apoptosis signal-regulating kinase 1. **2022**, 13, ○
- 9 Anti-neuroinflammatory Effects and Brain Pharmacokinetic Properties of Selonsertib, an Apoptosis signal-regulating Kinase 1 Inhibitor, in mice. ○
- 8 Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study. ○
- 7 Emerging pharmacological treatment options for MAFLD. **2022**, 13, 204201882211424 ○
- 6 Targeting integrin pathways: mechanisms and advances in therapy. **2023**, 8, 1
- 5 Metabolic-associated fatty liver disease: pharmacological management. **2023**, 319-341 ○
- 4 The burden of nonalcoholic steatohepatitis (NASH) in the United States. **2023**, 23, ○
- 3 Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis. **2023**, 324, G378-G388 ○
- 2 Economic Burden and Patient-Reported Outcomes of Nonalcoholic Fatty Liver Disease. **2023**, 27, 483-513 ○
- 1 Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017-2018. 10, ○